Top-Rated StocksTop-RatedNASDAQ:CNTA Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis $16.81 -0.36 (-2.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$17.34 +0.53 (+3.15%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Centessa Pharmaceuticals Stock (NASDAQ:CNTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CNTA alerts:Sign Up Key Stats Today's Range$16.67▼$17.4550-Day Range$11.86▼$17.1752-Week Range$9.10▼$19.09Volume851,202 shsAverage Volume1.04 million shsMarket Capitalization$2.25 billionP/E RatioN/ADividend YieldN/APrice Target$28.10Consensus RatingBuy Company Overview Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Read More Centessa Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreCNTA MarketRank™: Centessa Pharmaceuticals scored higher than 61% of companies evaluated by MarketBeat, and ranked 375th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCentessa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCentessa Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Centessa Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Centessa Pharmaceuticals are expected to grow in the coming year, from ($1.60) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Centessa Pharmaceuticals is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Centessa Pharmaceuticals is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentessa Pharmaceuticals has a P/B Ratio of 5.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Centessa Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.29% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently decreased by 4.43%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCentessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthCentessa Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.29% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently decreased by 4.43%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.72 News SentimentCentessa Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Centessa Pharmaceuticals this week, compared to 5 articles on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Centessa Pharmaceuticals insiders have bought 83.52% more of their company's stock than they have sold. Specifically, they have bought $5,866,687.00 in company stock and sold $3,196,684.00 in company stock.Percentage Held by InsidersOnly 7.09% of the stock of Centessa Pharmaceuticals is held by insiders.Percentage Held by Institutions82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Centessa Pharmaceuticals' insider trading history. Receive CNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTA Stock News HeadlinesInsider Selling: Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Sells 8,322 Shares of StockJuly 31 at 6:37 AM | insidertrades.comCentessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Sells $155,600.00 in StockJuly 26, 2025 | insidertrades.comThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.August 2 at 2:00 AM | InvestorPlace (Ad)Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Sells $875,600.00 in StockJuly 22, 2025 | insidertrades.comTruist Initiates Buy on Centessa Pharmaceuticals (CNTA) with $30 PT, Cites Orexin Drug PotentialAugust 1 at 3:28 AM | msn.comHead to Head Review: Centessa Pharmaceuticals (NASDAQ:CNTA) vs. Nutriband (NASDAQ:NTRB)August 1 at 2:01 AM | americanbankingnews.comTruist Securities Initiates Coverage of Centessa Pharmaceuticals plc - Depositary Receipt () (CNTA) with Buy RecommendationJuly 23, 2025 | msn.comCentessa Pharmaceuticals Advances Neurological Drug ORX142 to Clinical TrialsJuly 15, 2025 | msn.comSee More Headlines CNTA Stock Analysis - Frequently Asked Questions How have CNTA shares performed this year? Centessa Pharmaceuticals' stock was trading at $16.75 on January 1st, 2025. Since then, CNTA stock has increased by 0.4% and is now trading at $16.81. How were Centessa Pharmaceuticals' earnings last quarter? Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.15. When did Centessa Pharmaceuticals IPO? Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering on Friday, May 28th 2021. The company issued 15,000,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers. Who are Centessa Pharmaceuticals' major shareholders? Top institutional shareholders of Centessa Pharmaceuticals include Tanager Wealth Management LLP (0.45%), TD Asset Management Inc (0.41%), Platinum Investment Management Ltd. (0.22%) and HighMark Wealth Management LLC (0.18%). Insiders that own company stock include Antoine Yver, Arjun Goyal, David M Chao, Saurabh Saha, Mario Alberto Accardi, Thomas Templeman, Gregory M Weinhoff, Tia L Bush, Iqbal J Hussain, Harris Rotman and Karen M Anderson. View institutional ownership trends. How do I buy shares of Centessa Pharmaceuticals? Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Centessa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Centessa Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST). Company Calendar Last Earnings5/12/2025Today8/02/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTA CIK1847903 Webwww.centessa.com Phone44-73-9178-9784FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Price Target for Centessa Pharmaceuticals$28.10 High Price Target$38.00 Low Price Target$6.00 Potential Upside/Downside+67.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$235.76 million Net MarginsN/A Pretax Margin-1,467.24% Return on Equity-40.22% Return on Assets-29.95% Debt Debt-to-Equity Ratio0.28 Current Ratio14.37 Quick Ratio14.37 Sales & Book Value Annual Sales$6.85 million Price / Sales327.91 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book5.51Miscellaneous Outstanding Shares133,620,000Free Float124,145,000Market Cap$2.25 billion OptionableOptionable Beta1.47 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CNTA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.